BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†1
*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)1
†BRILIQUE (ticagrelor) 90mg twice daily in combination with acetylsalicylic acid (ASA) is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg twice daily is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment
Mode of Action
BRILIQUE (ticagrelor) is an orally active P2Y12 receptor inhibitor
- BRILIQUE (ticagrelor) is a cyclopentyltriazolopyrimidine, a different drug class vs thienopyridines1
- It binds reversibly to P2Y12 receptors, preventing ADP-mediated platelet activation1
- Unlike thienopyridines, BRILIQUE (ticagrelor) is an active compound that is absorbed in the intestine and does not require biotransformation37
- More rapid platelet inhibition vs clopidogrel38
- No variability in exposure due to genetic polymorphisms (CYP2C19 and ABCB1),37, 39 which can affect outcomes40, 41
ADP, adenosine diphosphate
BRILIQUE (ticagrelor) works via a dual pathway
BRILIQUE (ticagrelor) acts on the platelet and adenosine pathways:
‖BRILIQUE (ticagrelor) is an ENT-1 (Equilibrative Nucleoside Transporter) adenosine uptake inhibitor, the clinical relevance of which is under investigation.
¶BRILIQUE (ticagrelor) should be stopped 5 days prior to elective surgery if antiplatelet effect is not desired CPTP = cyclo-pentyl-triazolo-pyrimidine.